Mild Gestational Diabetes and Adverse Pregnancy Outcome : A Systemic Review and Meta-Analysis by Yarandi, Razieh Bidhendi et al.
SYSTEMATIC REVIEW
published: 05 July 2021
doi: 10.3389/fmed.2021.699412







Poznan University of Medical
Sciences, Poland
Nazan Yurtcu,






This article was submitted to
Obstetrics and Gynecology,
a section of the journal
Frontiers in Medicine
Received: 23 April 2021
Accepted: 07 June 2021
Published: 05 July 2021
Citation:
Bidhendi Yarandi R, Vaismoradi M,
Panahi MH, Gåre Kymre I and
Behboudi-Gandevani S (2021) Mild
Gestational Diabetes and Adverse




Mild Gestational Diabetes and
Adverse Pregnancy Outcome: A
Systemic Review and Meta-Analysis
Razieh Bidhendi Yarandi 1, Mojtaba Vaismoradi 2, Mohammad Hossein Panahi 3,
Ingjerd Gåre Kymre 2 and Samira Behboudi-Gandevani 2*
1Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, 2 Faculty of Nursing and
Health Sciences, Nord University, Bodø, Norway, 3Department of Epidemiology, School of Public Health and Safety, Shahid
Beheshti University of Medical Sciences, Tehran, Iran
Background and Objectives:Mild gestational diabetes (GDM) refers to the gestational
hyperglycemia, which does not fulfill the diagnostic criteria for GDM. The results of studies
on adverse pregnancy outcomes among women with mild GDM are controversial.
Therefore, the aim of this systematic review and meta-analysis was to investigate the
impact of mild GDM on the risk of adverse maternal and neonatal outcomes.
Methods: A thorough literature search was performed to retrieve articles that
investigated adverse maternal and neonatal outcomes in women with mild GDM in
comparison with non-GDM counterparts. All populations were classified to three groups
based on their diagnostic criteria for mild GDM. Heterogeneous and non-heterogeneous
results were analyzed using the fixed/random effects models. Publication bias was
assessed using the Harbord test. DerSimonian and Laird, and inverse variance methods
were used to calculate the pooled relative risk of events. Subgroup analysis was
performed based on mild GDM diagnostic criteria. Quality and risk of bias assessment
were performed using standard questionnaires.
Results: Seventeen studies involving 11,623 pregnant women with mild GDM and
53,057 non-GDM counterparts contributed to the meta-analysis. For adverse maternal
outcomes, the results of meta-analysis showed that the women with mild GDM had
a significantly higher risk of cesarean section (pooled RR: 1.3, 95% CI 1.2–1.5),
pregnancy-induced hypertension (pooled RR: 1.4, 95% CI 1.1–1.7), preeclampsia
(pooled RR: 1.3, 95%CI 1.1–1.5) and shoulder dystocia (pooled RR: 2.7, 95%CI 1.5–5.1)
in comparison with the non-GDMpopulation. For adverse neonatal outcomes, the pooled
relative risk of macrosomia (pooled RR = 0.4, 95% CI: 1.1–1.7), large for gestational age
(pooled RR = 1.7, 95% CI: 1.3–2.3), hypoglycemia (pooled RR = 1.6, 95% CI: 1.1–2.3),
hyperbilirubinemia (pooled RR = 1.1, 95% CI: 1–1.3), 5min Apgar <7 (pooled RR = 1.6,
95% CI: 1.1–2.4), admission to the neonatal intensive care unit (pooled RR = 1.5, 95%
CI: 1.1–2.1), respiratory distress syndrome (pooled RR = 3.2, 95% CI: 1.8–5.5), and
preterm birth (pooled RR = 1.4, 95% CI: 1.1–1.7) was significantly increased in the mild
GDM women as compared with the non-GDM population. However, the adverse events
of small for gestational age and neonatal death were not significantly different between
the groups. Analysis of composite maternal and neonatal outcomes revealed that the
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risk of those adverse outcomes in the women with mild GDM in all classifications were
significantly higher than the non-GDM population. Also, the meta-regression showed
that the magnitude of those increased risks in both composite maternal and neonatal
outcomes was similar.
Conclusion: The risks of sever adverse neonatal outcomes including small for
gestational age and neonatal mortality are not increased with mild GDM. However, the
increased risks of most adverse maternal and neonatal outcomes are observed. The risks
have similar magnitudes for all mild GDM diagnostic classifications.
Keywords: adverse maternal outcomes, adverse neonatal outcomes, mild gestational diabetes, meta-analysis,
diagnostic criteria
INTRODUCTION
Gestational diabetes (GDM) is one of the most common
endocrinopathies during pregnancy, affecting 4–12% of all
pregnancies (1). It occurs because of metabolic maladaptation
to insulin resistance, and mainly due to the hormonal changes
of pregnancy (2). It is well documented that GDM is strongly
associated with adverse feto-maternal and neonatal outcomes
such as macrosomia, preterm birth, and small for gestational
age (SGA) (3–5). Although glucose tolerance among pregnant
women with GDM reverts to normal shortly after delivery,
they are still potentially susceptible to type 2 diabetes mellitus
(T2DM), cardiovascular disease, and obesity (6–9).
In recent decades, there have been ongoing discussions
concerning the optimum diagnostic criteria for GDM across
the globe. The study of Hyperglycemia and Adverse Pregnancy
Outcomes (HAPO) showed that the increase of maternal
glycemia was associated with the enhancement of the risk of
adverse perinatal outcomes, with no obvious threshold at which
risks increased (10). Therefore, it becomes more difficult to
determine the optimal threshold for the diagnosis of and the
treatment of GDM and accordingly, some international societies
recommend more stringent criteria with lower diagnostic
thresholds of glucose (11–14).
More controversies are observed when “mild” is added to
GDM. It refers to the gestational hyperglycemia that does not
fulfill the diagnostic criteria for GDM. With more strict criteria
are used for mild GDM, the sensitivity of diagnosis is likely to
be increased at the expense of the specificity, which may allow
the identification of previously ignored risks, or may result in the
over medicalization of healthy pregnancies.
Meanwhile, the exact definition of the milder form of GDM
and its effect on adverse pregnancy outcomes are not clearly
understood. Current evidence shows conflicting results about
the relationship between mild GDM and adverse pregnancy
outcomes (15). Although the risk of adverse pregnancy outcomes
among women with mild GDM has been shown to be greater
than the non-GDM population (15–21), this finding has not
been confirmed (16, 22, 23). Therefore, there is a need to
improve our knowledge about the accurate estimation of the
risk of adverse maternal and neonatal outcomes. The aim of
this systematic review and meta-analysis was to investigate the
impact of mild GDM on the risk of adverse maternal and
neonatal outcomes.
MATERIALS AND METHODS
This systematic review and meta-analysis was conducted based
on the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) (24). The review question was: Does
untreated mild GDM increase the risk of adverse maternal
and neonatal outcomes compared to non-GDM counterparts?
The PICO statement was framed as follows: Patients: pregnant
women with mild GDM, Intervention: none, Comparison:
non-GDM pregnant women, Outcome: adverse maternal and
neonatal outcomes.
The following research objectives were addressed:
◦ To study the pooled risk of adverse single and composite
maternal outcomes among pregnant women with mild
GDM compared to non-GDM counterparts, regardless of
diagnostic criteria;
◦ To study the pooled risk of adverse single and composite
neonatal outcomes among pregnant women with mild
GDM compared to non-GDM counterparts, regardless of
diagnostic criteria;
◦ To study the pooled risk of adverse single and composite
maternal outcomes among pregnant women with mild GDM
compared to non-GDM counterparts, with the consideration
of various diagnostic criteria;
◦ To study the pooled risk of adverse single and composite
neonatal outcomes among pregnant women with mild
GDM compared to non-GDM counterparts, regardless of




(i) definition of mild GDM or gestational hyperglycemia;
(ii) specification of screening strategies and the blood sugar’s
threshold in the screening test;
(iii) report of one short-term single maternal and neonatal
outcome of GDM;
(iv) description of the frequency or prevalence of adverse events;
(v) comparison of adverse pregnancy outcomes between the
mild GDM group and the non-GDM group without
receiving any treatment;
(vi) report of clear data about undergoing treatment or not.
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The use of anti-diabetic treatments including physical exercise,
diet therapy and/or any medication for patients with mild
GDM, and the presence of glucose intolerance or diabetes
in the population of studies led to exclusion. Also, reviews,
commentaries, editorials, letters, conference proceedings, and
case reports were excluded.
Search Strategy
The databases of PubMed (including Medline), Web of Science,
and Scopus were searched in order to retrieve empirical studies
published in English language without time limitations and
until May 2020. In addition, the search coverage was improved
through performing a manual search in the bibliographic details
of selected studies. Relevant keywords and MeSH terms were
identified and used to develop search phrases using the Boolean
method with AND/OR operators (Supplementary Table 1).
Selection of Studies and Extraction of Data
The authors independently screened titles, abstracts, and full texts
of retrieved studies against the inclusion and exclusion criteria.
For each eligible study, the following data were extracted: name
of the first author, title of journal, year of publication, research
country, method, population and samples, demographic, and
health-related characteristics such as age group, body mass index
(BMI), strategies used for the screening of mild GDM and
related values such as blood sugar tests, and the frequency
and prevalence of adverse events. Errors in the data entry and
extraction were prevented through performing a control check by
another author on the final data used in the meta-analysis against
data in original publications.
Study Subgroups and Outcomes
To facilitate the clinical interpretation of the results of the
included studies, they were classified into 3 subgroups based on
the mild GDM diagnostic criteria as follows:
Group 1: screened based on oral glucose tolerance test
(OGTT) with 75 g 2-h. Mild GDM diagnosis was based on
only one abnormal value in OGTT-75 g;
Group 2: screened based on 1-h glucose challenge test (GCT-
50 g), followed by 3-h oral glucose test (OGT-100 g). Mild
GDM diagnosis was based on only abnormal values for GCT
and normal values for OGTT-g;
FIGURE 1 | Flow diagram of the search strategy and study selection.















































TABLE 1 | Demographic and health-related characteristic of the studies’ participants.
References Country Screening test Mild GDM diagnostic criteria Non-GDM group characteristics Mild GDM group characteristics
Black et al. (15) USA OGTT-75 g-2 h 1. Either BS-1 h ≥ 180 mg/dL or BS-2 h > 153
mg/dL and FPG < 92 mg/dL
2. FPG ≥ 92 mg/dL and both BS-1 h < 180
mg/dL
3. BS-1 h ≥ 180 mg/dL and both BS-2 h ≥ 153
but FBS < 92 mg/dL and BS-2 h < 153 mg/dL
4. FBS ≥ 92 mg/dL and either BS-1 h ≥ 180
mg/dL and/or BS-2 h ≥ 153 mg/dL
N = 7,020, Age: 28.6 (5.9), BMI: 26.9
(5.8)
1. N = 391, Age: 32.1 (5.4), BMI: 28.1 (5.6)
2. N = 886, Age: 30.4 (5.6), BMI: 30.8 (7.1)
3. N = 83, Age: 32.3 (5.2), BMI: 27.5 (4.7)
4. N = 331, Age: 32.0 (5.1), BMI: 31.8 (7.0)
Bo et al. (16) Italy GCT-50-1 h g followed by
OGTT-100 g-3 h
1. Only one abnormal value in OGTT 100 g: FPG
> 5.3 mmol/L or BS-1 h > 10.0 mmol/L or
BS-2 h > 8.6 mmol/L or BS-3 h > 7.8 mmol/L
2. GCT ≥ 7.8 mmol/L and OGTT 100 g-negative
N = 100, Age: 30.8 (4.2), BMI: 23.1 (4.6) N = 350, Age: 31.8 (4.3), BMI: 23.5 (4.8)
Bonomo et al. (29) Italy GCT-50-1 h g followed by
OGTT-100 g-3 h
GCT ≥ 7.8 mmol/L and OGTT 100 g-negative N = 150, Age: 31.1 (4.4), BMI: 23.0 (4.1) N = 150, Age: 30.7 (5.1), BMI: 23.0 (4.5)
Cakar et al. (17) Turkey GCT-50-1 h g followed by
OGTT-100 g-3 h
GCT ≥ 7.8 mmol/L and OGTT 100 g- negative N = 160, Age: 29.2 (6.1), BMI:- N = 198, Age: 28.2 (5), BMI:-
Hedderson et al. (19) USA GCT-50-1 h g followed by
OGTT-100 g-3 h
GCT ≥ 140 mg/dL and OGTT 100 g- negative N = 38,515, Age: -, BMI:- N = 5,352, Age: -, BMI:-
Kanai et al. (22) Japan GCT-50-1 h g followed by
OGTT-75 g-2 h
One elevated value on FBS > 92, BS-1 h > 180
mg/dL, BS-2 h > 153 mg/dL
N = 135, Age: 32.6 (4.9), BMI: 20.9
(19.5–23.2)
N = 38, Age: 34.5 (4.8), BMI: 22.0
(20.1–23.8)
Kaymak et al. (20) Turkey GCT-50-1 h g followed by
OGTT-100 g-3 h
1. GCT ≥ 7.8 mmol/L and OGTT 100 g- negative
2. Only one abnormal value in OGTT 100 g: FPG
≥ 5.3 mmol/L or BS-1 h ≥ 10.0 mmol/L or
BS-2 h ≥8.6 mmol/L or BS-3 h ≥7.8 mmol/L
N = 479, Age: 25.2 (4.8), BMI:- 1. N = 401, Age: 27.4 (5.5), BMI:-
2. N = 80, Age: 29.4 (5.3), BMI:-
Landon et al. (21) USA GCT-50-1 h g followed by
OGTT-100 g-3 h
1. GCT ≥ 135 mg/dL and OGTT 100 g- negative
2. FBS < 95 mg/dL and two or more value of
BS-1 h > 180 mg/dL, BS-2 h > 155 mg/dL,
BS-3 h > 140 mg/dL
N = 437, Age: 25.1 (5.3), BMI:- 1. N = 931, Age: 27.4 (5.5), BMI:-
2. N = 473, Age: 28,9 (5.6), BMI:-
Lao et al. (30) China OGTT-75 g- 2 h 1. BS-2 h: 6–6.9 mmol/L
2. BS-2 h: 7–7.9 mmol/L
N = 304, Age: 28.6 (4.6), BMI: 21.5 (2.6) 1. N = 386, Age: 29.6 (4.6), BMI: 21.7 (2.7)
2. N = 304, Age: 30.8 (4.4), BMI: 21.8 (2.8)
Lao et al. (23) China OGTT-75 g- 2 h BS-2 h: 125–142 mg/dL N = 1,072, Age: 31.9, BMI: 22.8 N = 400, Age: 32.2, BMI: 23.3
Lee et al. (31) Korea GCT-50-1 h g followed by
OGTT-100 g-3 h
GCT ≥ 7.8 mmol/L and OGTT 100 g- negative N = 819, Age: 33.9 (3.8), BMI: 20.5 (2.4) N = 476, Age: 33.2 (3.9), BMI: 21.3 (3.5)
Martínez-Cruz et al. (32) México OGTT-75 g-2 h One elevated value on FBS > 92, BS-2 h > 153
mg/dL
N = 282, Age: 30.4 (6.5), BMI: 27.1 (4.0) N = 282, Age: 29.9 (7.2), BMI: 27.3 (4.6)
Miyakoshi et al. (33) Japan GCT-50-1h g followed by
OGTT-75 g-2 h
One elevated value on FBS > 100, BS-1 h > 180
mg/dL, BS-2 h > 150 mg/dL
N = 2,463, Age: 32.4 (4.3), BMI: 20.2
(2.4)
N = 139, Age: 33.8 (37), BMI: 20.5 (3.0)
Ostlund et al. (34) Sweden Random
blood glucose level followed by
OGTT-75 g-2 h
FBS < 6.7 mmol/L and BS-2 h: 9.0–11.0 mmol/L. N = 812, Age: 30.0 (5.0), BMI: 24.1 (4.0) N = 213, Age: 32.5 (5.0), BMI: 27.5 (5.4)
Park et al. (35) South
korea
GCT-50-1 h g followed by
OGTT-100 g-3 h
One elevated value on FBS > 95 mg/dL, BS-1 h
> 180 mg/dL, BS-2 h > 155 mg/dL, BS-3 h >
140 mg/dL
N = 93, Age: 32.8 (3.5), BMI: 20.9
(19.6-23.7)






























































































































































































































































































































































































































































































































































Group 3: screened based on 1-h GCT-50 g, followed by 3-h
OGT −100 g. Mild GDM diagnosis was based on only one
abnormal value in OGTT 100 g.
The composite outcome of adverse maternal outcomes and
the single maternal events of cesarean section, preeclampsia
and pregnancy-induced hypertension were selected. Also, the
composite outcome of adverse neonatal outcomes and the
single neonatal events of macrosomia, large for gestational age
(LGA), SGA, hypoglycemia, hyperbilirubinemia, admission to
the neonatal intensive care unit (NICU), respiratory distress
syndrome (RDS), shoulder dystopia, neonatal death, and preterm
birth and Apgar score in 5min less than 7 were chosen.
Quality and Risk of Bias Assessment
Quality of the studies was critically appraised for their
methodology and presentation of their results. Two reviewers
who were blinded to the journal title, study author and
institution, evaluated the quality of each study independently.
The quality of observational studies was assessed using the
modification of the Newcastle–Ottawa Quality Assessment Scale
(25). Studies with scores above 6 were considered as high
quality, 3–5 moderate, and below 3 low quality. The CONSORT
checklist was used to appraise RCTs and studies with scores
≥70% were judged as high-quality, 40–70% moderate, 20–
40% low, and <20% very low (26). The risk of bias was
assessed using the ROBINS for interventional studies (27) and
Cochrane Collaboration’s tool for assessing risk of bias for
cohort studies (28). The authors categorized the risk of bias
as high risk, low risk, and some concern of risk of bias.
Statistical Analysis
The software package STATA (version 14; STATA Inc., College
Station, TX, USA) was applied to conduct statistical analysis.
Heterogeneity between the studies was assessed using Cochran’s
Q statistic, and heterogeneity was detected with a p-value <0.05.
The random/fixed effects models that calculated the pooled
effect were used to assess heterogeneous and non-heterogeneous
results. The Harbord test helped assess publication bias. In
case of significant publication bias, the trim and fill method
was used for adjustment. The pooled Risk Ratio (RR) and
95% CI of events in both groups were calculated using the
DerSimonian and Laird, and the inverse variance methods.
Meta-regression explored the association between the risk of
adverse outcome of mild GDM and its diagnostic criteria as the
heterogeneity source. The effect of each individual study on the
overall summary estimate of meta-analysis was examined using
the sensitivity analysis. The influence analysis graph indicating
re-estimated meta-analysis omitting each study was drawn.
The level of statistical significance was considered at p-value
of <0.05.
RESULTS
Search and Quality Appraisal
The flow diagram of the search strategy and study selection
has been presented in Figure 1. The search strategy yielded
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TABLE 2 | Heterogeneity, estimation of publication bias, and meta-analysis for comparing the relative risk of adverse maternal and neonatal outcomes.
Outcome Sample size Publication bias Heterogeneity Pooled overall
Harbord test* P-value* RR (95% CI)*
Mild GDM Non-GDM
Composite adverse maternal outcome 25,451 160,353 0.061 0.001 1.3 (1.2, 1.5)
Cesarean section 8,223 43,465 0.344 0.001 1.3 (1.2, 1.5)
Pregnancy induced hypertension 8,819 72,398 0.287 0.001 1.4 (1.1, 1.7)
Shoulder dystocia 2,132 2,111 0.927 0.611 2.7 (1.5, 5.1)
Preeclampsia 6,277 42,379 0.932 0.747 1.3 (1.1, 1.5)
Composite adverse neonatal outcome 46,477 275,351 0.003* 0.001 1.1 (1.0, 1.2)*
Macrosomia 8,113 45,048 0.213 0.001 1.4 (1.1, 1.7)
LGA 11,750 74,944 0.170 0.000 1.7 (1.3, 2.3)
SGA 8,382 45,605 0.068 0.029 1.0 (0.7, 1.2)
Hypoglycemia 1,322 2,488 0.269 0.509 1.6 (1.1, 2.3)
Hyperbilirubinemia 3,001 29,729 0.029* 0.190 1.1 (1.0, 1.3)*
Neonatal death 831 1,058 0.143 0.339 1.0 (0.3, 2.9)
5min Apgar <7 1,012 2,138 0.329 0.937 1.6 (1.1, 2.4)
NICU admission 922 1,414 0.631 0.972 1.5 (1.1, 2.1)
RDS 880 1,281 0.393 0.699 3.2 (1.8, 5.5)
Preterm birth 10,264 1,646 0.956 0.001 1.4 (1.1, 1.7)
GD, Gestational diabetes; LG, Large for gestational age; SGA, Small for gestational age; NICU, Neonatal intensive care Unit; RDS, Respiratory distress syndrome.
Bold values indicate statistical significance.
*Obtained from the trim and fill method of publication bias adjustment.
475 potentially relevant articles, of which 59 articles were
identified suitable for further full-text appraisals. Finally, 17
studies were chosen for the meta-analysis that included data of
11,623 pregnant women with mild GDM and 53057 non-GDM
counterparts. The characteristics of the included studies have
been summarized in Table 1.
Supplementary Tables 2, 3 show the details of quality
assessment performed on the included studies. The quality of
fifteen studies were high (15–17, 19, 20, 22, 23, 30–37), one
moderate (21), and one low quality (29), but no study had very
low quality.
Fifteen studies used the cohort design (15–17, 19, 20, 22, 23,
30–37) and two others used the interventional design (21, 29).
Three studies were conducted in the USA (15, 19, 21), 6 in East
Asia including Japan, South Korea, and China (22, 23, 30, 31, 33,
35), 5 in Europe (16, 29, 34, 36, 37), 2 in Turkey (17, 20), and one
in Mexico (32).
Thirteen studies applied the two-step screening approach
using one 1-h GCT with 50 g glucose followed by 3-h OGTT
with 100 glucose (16, 17, 19–22, 29, 31–33, 35, 37); among these
studies, a total of 5 studies used the just elevated abnormal value
of GCT (16–18, 29, 31), and others used normal GCT with one
(16, 20, 22, 35–37) or two elevated abnormal values of OGTT
100 g (21) as the mild GDM diagnostic definition. As well, 4
applied the one-step screening approach using 2-h OGTT with
75 glucose (15, 23, 30, 34) and all of them used the one elevated
abnormal value in those tests as mild GDM diagnostic criteria.
According to those used definitions, 6 studies were classified into
group 1 (15, 22, 23, 30, 32, 33), 7 into group 2 (16, 17, 19–21, 29,
31), and 7 into group 3 (16, 20, 21, 33, 35–37).
Meta-Analysis
The overall pooled RR (95%CI) of adversematernal and neonatal
outcomes, heterogeneity, and estimation of publication bias in
women with mild GDM compared to non-GDM counterparts
has been shown in Table 2.
In terms of adverse maternal outcomes, the women with mild
GDM had a significantly higher risk of cesarean section (pooled
RR: 1.3, 95% CI 1.2–1.5), pregnancy induced hypertension
(pooled RR: 1.4, 95% CI 1.1–1.7), preeclampsia (pooled RR: 1.3,
95% CI 1.1–1.5), and shoulder dystocia (pooled RR: 2.7, 95% CI
1.5–5.1) in comparison with the non-GDM population, Table 2
and Figure 2.
In terms of adverse neonatal outcomes, the pooled relative
risk of macrosomia (pooled RR = 0.4, 95% CI: 1.1–1.7), LGA
(pooled RR = 1.7, 95% CI: 1.3–2.3), hypoglycemia (pooled RR
= 1.6, 95% CI: 1.1–2.3), hyperbilirubinemia (pooled RR = 1.1,
95% CI: 1–1.3), 5min Apgar <7 (pooled RR = 1.6, 95% CI:
1.1–2.4), admission to the NICU (pooled RR = 1.5, 95% CI: 1.1–
2.1), RDS (pooled RR = 3.2, 95% CI: 1.8–5.5) and preterm birth
(pooled RR = 1.4, 95% CI: 1.1–1.7) significantly increased in the
treated group as compared with the non-GDM group, Table 2
and Figure 3. However, the adverse events of SGA and neonatal
death were not significantly different between the groups (Table 2
and Figure 3).
Subgroup Analysis and Meta-Regression
Due to the lack of data, subgroup analysis for single outcomes
could not be performed, but the analysis of composite maternal
and neonatal outcomes revealed that the risk of those adverse
outcomes in women with mild GDM in all classifications were
Frontiers in Medicine | www.frontiersin.org 6 July 2021 | Volume 8 | Article 699412
Bidhendi Yarandi et al. Mild Gestational Diabetes and Pregnancy Outcome
FIGURE 2 | Forest plot of pooled relative risk of adverse maternal events.
significantly higher than the non-GDM population (Table 3 and
Figures 4, 5). The meta-regression showed that the magnitude of
those increased risks in both composite maternal and neonatal
outcomes were similar. In addition, subgroup analyses with the
exclusion of studies that fulfilled IADPSG (HAPO) criteria was
performed, but the results remained unchanged (Figures 6, 7).
Sensitivity Analysis, Publication Bias and
Risk of Bias
Sensitivity analyses showed the robustness of pooled RR
indicating no major impact of any single study on pooled
RR in both maternal and neonatal adverse outcomes
(Supplementary Figures 1, 2).
According to the Harbord test, there was no publication bias
for most analyses in the meta-analysis. However, a significant
publication bias was found, in the meta-analyses of composite
adverse neonatal outcome and hyperbilirubinemia, which was
corrected by the trim and fill method of adjustment (Table 2).
A low risk of bias was observed in the appraised domains
(Supplementary Figures 3, 4). Cohort studies had a low risk
of bias for the selection of exposed and non-exposed cohorts,
assessment of exposure, presence of the outcome of interest
at the start of the study, outcome assessment, and adequacy
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FIGURE 3 | Forest plot of pooled relative risk of adverse neonatal events.
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TABLE 3 | Results of heterogeneity, estimation of publication bias, and meta-analysis for comparing the relative risk of adverse maternal and neonatal outcomes based
on diagnostic criteria.
Outcome Sample size Publication bias Heterogeneity Pooled overall Meta-regression
Harbord test P-value* RR (95% CI)* P-value
Mild GDM Non-GDM
Composite adverse maternal outcome
Sub-group 1 4,666 34,114 0.412 0.001 1.2 (1.0, 1.5) 0.840
Sub-group 2 17,707 118,819 0.186 0.001 1.4 (1.2, 1.6)
Sub-group 3 3,078 7,420 0.411 0.001 1.6 (1.3, 1.9)
Composite adverse neonatal outcome
Sub-group 1 1,2045 97,603 0.796 0.001 1.5 (1.2, 1.8) 0.112
Sub-group 2 2,583 163,959 0.985 0.001 1.3 (1.1, 1.5)
Sub-group 3 8,247 13,789 0.189 0.198 1.5 (1.3, 1.8)
GDM, Gestational diabetes; RR, Relative risk.
*Bold values indicate statistical significance.
FIGURE 4 | Forest plot of pooled relative risk of adverse maternal events in subgroups.
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FIGURE 5 | Forest plot of pooled relative risk of adverse neonatal events in subgroups.
of follow up of cohorts. However, around 7% of them had a
probable low risk of bias in controlling prognostic variables and
one third of them had a high risk of bias in the assessment of
the presence or absence of prognostic factors and controlling
prognostic variables. Two interventional studies had a low risk
of bias in the measurement of outcomes and selection of the
reported results and had some concern regarding bias in the
randomization process, intervention, and missing outcome data.
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FIGURE 6 | Forest plot of pooled relative risk of adverse maternal events with the exclusion of studies that fulfilled the IADPSG (HAPO) criteria.
DISCUSSION
This meta-analysis indicated that although mild GDM in
spite of not fulfilling the diagnostic criteria for GDM did
not increase the risk of sever adverse neonatal outcomes of
SGA and neonatal mortality, it increased the risks of most
adverse maternal and neonatal outcomes including cesarean
section, shoulder dystocia, macrosomia, LGA, preeclampsia,
pregnancy induced hypertension, preterm birth, hypoglycemia,
hyperbilirubinemia, low Apgar score, RDS, and admission to
the NICU compared to subjects with completely normal glucose
tolerance. Moreover, subgroup analysis based on the definition
demonstrated that all mild GDM criteria used by available
studies similarly increased the risk of composite maternal and
neonatal outcomes.
Gestational hyperglycemia is usually the result of β-cell
dysfunction, caused partly by hormones from the placenta and
partly by other obesity and pregnancy related factors that are
not fully understood on the background of chronic insulin
resistance during pregnancy. Altered carbohydrate metabolism
may cause arteriosclerosis and dysfunction in the glomerular
filtration leading to adversematernal outcomes during pregnancy
(38). Moreover, it is demonstrated that maternal hyperglycemia
is readily transported across placenta to fetus and stimulates
the fetus’s endogenous production of insulin and insulin-like
growth factor 1 (IGF-1) (2, 39). Together, these can cause
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FIGURE 7 | Forest plot of pooled relative risk of adverse neonatal events with the exclusion of studies that fulfilled the IADPSG (HAPO) criteria.
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fetal overgrowth, often resulting in macrosomia at birth. As
well, excess fetal insulin production can cause hypoglycemia,
which can contribute to brain injury if not properly managed
(40). Moreover, fetal hyperinsulinemia has been suggested to be
associated with delayed pulmonary maturation, which is also the
risk factor for neonatal respiratory morbidity (41).
Although it has long been recognized that women with GDM
are at the increased risk of adverse maternal and fetal outcomes
if optimal care is not provided, the relationship of milder form
of GDM to various perinatal risks has been less documented.
As noted by the HAPO study (10), GDM is a wide range of
maternal hyperglycemia, in which blood glucose levels stay along
a continuum and is correlated with a wide spectrum of metabolic
abnormalities and conferring the varying degrees of pregnancy-
related risk (42). In this respect, there were no obvious thresholds
at which the risk for any of perinatal outcomes increased in
a more intense manner, instead of rising along a continuum.
Consistent with the findings of the HAPO study (10), our meta-
analysis confirm that the ‘borderline’ situations of hyperglycemia
can alter glucose metabolism in pregnancy, and subsequently
increase the risk of many important adverse pregnancy outcomes
compared to the non-GDM population.
In agreement with our finding, a recently published meta-
analysis of 10 interventional studies reported that the standard
treatment of GDM through diet therapy and insulin improved
adverse pregnancy outcomes in women with the milder form
of GDM (43). In this study, the risk of adverse pregnancy
outcome in a total of 3,317 pregnant women with borderline
hyperglycemia who received the standard GDM treatment
was compared with 4,407 untreated counterparts. Therefore,
treatment reduced the risk of macrosomia, LGA and shoulder
dystocia without enhancing the risk of SGA in these women (43).
The lack of a standard definition for mild GDM during
pregnancy causes that different studies on this topic produce
various definitions. Therefore, the studies’ samples consist of
women with various levels of glucose intolerance. Moreover,
it is suggested that the risks of different adverse pregnancy
outcomes vary depending on which single or combined OGTT
thresholds are equaled or exceeded (42). It should be noted that
all those definitions did not fulfill the GDM criteria. Moreover,
to determine whether those definitions could increase the risk of
adverse outcomes, mild GDM definition was classified. However,
the subgroup analysis revealed that the risk of composite
adverse outcomes in women with mild GDM in all definitions
were significantly higher than the non-GDM population and
importantly the magnitude of those increased risks remained
similar. It should be noted that the lack of data hindered the
analysis of single outcomes; therefore, the results of composite
outcomes must be interpreted with caution, which raises concern
that composite outcomemay not reflect the mild disease andmay
confer the higher risk compared to adverse single outcome.
In addition, mild GDM did not increase the risk of sever
adverse neonatal outcomes including neonatal death and SGA.
It is believed that these outcomes often are associated with
severe glucose intolerance than that included to this review. The
participants of the present meta-analysis had a normal level of
fasting maternal glucose. It has been reported that the threshold
of an enhanced risk of neonatal hypoglycemia is not observed
until the fasting maternal glucose level exceeds 100 mg/dL (5.6
mmol/L) (10, 15, 44).
The study limitations should be considered during the
interpretation of findings. A lack of unique definition for
mild GDM and adverse pregnancy outcomes influenced the
data analysis. The sample size of the studies was low. Also,
data was collected in developed counties, which should not
be extrapolated to women living in developing countries with
different lifestyles, ethnicities, and access to healthcare facilities.
Moreover subgroup-analysis based on fasting maternal glucose
results known as the adverse pregnant outcomes’ indicator (15)
were not carried out, because of lack of data. In addition, risk
factors for GDM including overweight and obesity, advanced
maternal age, and a family history or any form of diabetes were
not evaluated in our study, due to insufficient data in the original
studies. The short-term adverse outcomes of mild GDM were
assessed, but longer-term outcomes should be investigated in
future studies. Nonetheless, not enough power for reporting
statistically significant findings for other pregnancy outcomes
could be achieved.
CONCLUSION
The findings of our study support that the borderline situations
of gestational hyperglycemia, lower than diagnostic criteria
for GDM, can increase most adverse maternal and neonatal
outcomes. However, it does increase the risk of severe neonatal
outcomes of SGA and neonatal mortality. These findings can give
some clue to healthcare professionals for redefining criteria for
the diagnosis of GDM and to include those women with milder
form of disease. Well-defined studies with larger sample sizes are
needed to confirm our review results.
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